Thio-Miltefosine is primarily investigated for its potential in treating parasitic infections, particularly leishmaniasis, a disease caused by Leishmania parasites. It is being studied as an alternative to Miltefosine, with the aim of improving efficacy and reducing side effects. Additionally, its application extends to research in cancer therapy, where it is explored for its ability to induce apoptosis in cancer cells, offering a potential pathway for developing new anticancer drugs. Its use in these areas is still under clinical and experimental investigation, focusing on optimizing its therapeutic benefits.